Cesarean birth is among the most common surgeries in the world. In addition to its familiarity, the procedure carries surgical considerations that deserve continued attention, including wound healing, recovery experience, and postoperative complications. These realities invite continued reflection on how closure care can support both short-term recovery and long-term maternal well-being.
Recibio, Inc.a Houston-based medical technology company, approaches this landscape by thoughtfully acknowledging those considerations. Through its work, the company advocates the use of the mother’s own amniotic fluid during cesarean section wound closure as part of the standard of care, with the intention of promoting wound healing and influencing adhesion formation in a biologically aligned manner.
“From what we’re seeing, even small advances in wound care could have a significant influence on mothers, newborns, and the systems that support them,” says Geoffrey Jones, founder of Recibio. In this context, Recibio’s expertise focuses on how naturally available biological materials, already present during surgery, can be carefully reintegrated into care pathways.
Amniotic tissue and fluid have garnered sustained interest in regenerative medicine for their distinctive biological properties, demonstrating useful characteristics that modulate inflammation, provide microbial defense, and resist tissue adhesion to improve wound healing.
Research on amniotic derivative The materials describe their broad differentiation potential and immunologically compatible profile, qualities that have informed exploration in applications related to the skin, musculoskeletal system and organs. This body of work suggests that amniotic fluid offers a supportive biological environment for healing, one that reflects familiar processes of fetal development while still remaining suitable for adult tissues.
Recibio’s CeaLogic product line emerges from this scientific foundation with a focused clinical application. Designed specifically for women undergoing cesarean delivery, CeaLogic products allow for the immediate collection and reapplication of autologous amniotic fluid at the time of surgery. “Basically, we take something from the mother that would normally be donated or thrown away and use it to support her healing,” Jones explains. “As it depends on the patient’s own amniotic fluid, there is no chance of rejection and it is easily adapted to standard surgical practice.”
The mechanism guiding this approach focuses on taking advantage of the cells and bioactive components that are already present in the amniotic fluid. These elements are understood to participate in tissue signaling, modulation of inflammation and antimicrobial activity, creating conditions that can promote repair and at the same time prevent scar formation.
Research supported by Recibio adds clinical nuance to this understanding. In the study titled Collection and application of autologous amniotic fluid for closure of cesarean deliveryThe researchers demonstrated that amniotic fluid could be successfully collected and reapplied during closure using the CeaLogic system. Jones says, “During the six-week follow-up, participants reported consistently lower pain scores and no wound complications or infections. To me, that really demonstrates how feasible and reliable this approach is in everyday clinical practice.” The study emphasized the need for continued research while also underscoring the promise of this biologically informed technique.
Complementing these findings, a prospective clinical registry initiative at UTHealth Houston is exploring autologous amniotic fluid as an antimicrobial adjunct during cesarean delivery. According to the registration proposal, amniotic fluid contains defensins, lactoferrin and other peptides associated with antimicrobial activity, as well as properties that promote epithelialization and comfort during healing. By documenting outcomes such as wound appearance, patient experience and adverse events, the registry aims to generate real-world evidence on how this approach can work alongside existing prophylactic practices as part of the standard of care.
For patients, the implications extend beyond clinical metrics. “Birth is already an intense time. If we can support healing in a way that feels intuitive to the body, we offer mothers a path to recovery,” says Jones. Recibio’s perspective frames the use of autologous amniotic fluid as a way to endure less pain, greater comfort, and a sense of reassurance that healing stems from one’s own biology.
Scalability remains fundamental to this vision. Cesarean births often occur in regions where access to follow-up care varies widely. Recibio positions CeaLogic as adaptable in any environment where surgery is performed, from high-volume urban facilities to hospitals serving geographically isolated communities. “Because the system relies on materials already present during surgery and is integrated into established procedures, implementation can be more familiar,” Jones says. This practicality supports broader adoption, even in settings where the risk of infection carries greater consequences and resources may be limited.
“Our hope is that all mothers, regardless of where they give birth, receive the same thoughtful support at the time of closure,” shares Jones. “Using your own amniotic fluid honors the biology of birth and invites healing to continue naturally.” In this future, CeaLogic will be integrated into routine practice and recognized globally as a standard of care for cesarean delivery.
As cesarean section rates continue to influence obstetric landscapes worldwide, attention to healing at closure takes on renewed importance. Through research-backed exploration, biologically aligned design, and a focus on the patient experience, Recibio brings a human perspective to this conversation. The result is an evolving model of care that invites collaboration and thoughtful integration in the places where mothers and clinicians meet at one of life’s most significant thresholds.
